Loading patent…
AssigneeMount Sinai School of Medicine
InventorsDaniel P. Perl, Sharon Moalem
Estimating the term…
The present invention relates to methods for preventing or treating infectious diseases caused by extracellular microorganisms, such as bacteria and fungi, by systemically administering to a patient a compound containing gallium. The extracellular microorganisms targeted by the present methods include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), E. coli O157:H7, fluoroquinolone-resistant Salmonella typhi, and the like. Furthermore, in the present methods, gallium compounds can be co-administered with one or more conventional antimicrobial agents to treat infectious diseases with reduced risks of creating multi-drug resistant pathogens. The methods of the present invention is also applicable to those microorganisms, such as ulcer-causing Helicobacter pylori, complete eradication of which so far has been difficult to achieve.
A method for treating an infectious disease caused by methicillin-resistant Staphylococcus aureus (“MRSA”), said method comprising intravenously administering to a subject in need thereof a therapeutically effective amount of gallium maltolate, said MRSA being present in the bloodstream of said subject, wherein said therapeutically effective amount is sufficient to reduce the number of said MRSA in the bloodstream of said subject, to suppress the growth of said MRSA in the bloodstream of said subject, or to kill said MRSA in the bloodstream of said subject.
A method for treating an infectious disease caused by methicillin-resistant Staphylococcus aureus (“MRSA”), comprising co-administering to a subject in need thereof therapeutically effective amounts, individually or collectively, of gallium maltolate, and at least one additional antimicrobial agent, said MRSA being present in the bloodstream of said subject, wherein said gallium maltolate is administered intravenously, and wherein said therapeutically effective amount is sufficient to reduce the number of said MRSA in the bloodstream of said subject, to suppress the growth of said MRSA in the bloodstream of said subject or to kill said MRSA in the bloodstream of said subject.
A method for treating an infection in the bloodstream of a subject, said infection being by a methicillin-resistant Staphylococcus aureus (“MRSA”), said method comprising intravenously administering to a subject in need thereof a therapeutically effective amount of gallium maltolate, wherein said therapeutically effective amount is sufficient to reduce the number of said MRSA in the bloodstream of said subject, to suppress the growth of said MRSA in the bloodstream of said subject, or to kill said MRSA in the bloodstream of said subject.
Dependencies are inferred from the claim text.